Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases

Breast Cancer Research

Volumn 9, Issue 6, 2007, Pages

  Huijts, Petra EA ^a   Vreeswijk, Maaike PG ^a   Kroeze Jansema, Karin HG ^a   Jacobi, Catharina E ^a   Seynaeve, Caroline ^b   Krol Warmerdam, Elly MM ^a   Wijers Koster, Pauline M ^a   Blom, Jannet C ^b   Pooley, Karen A ^c   Klijn, Jan GM ^b   Tollenaar, Rob AEM ^a   Devilee, Peter ^a   van Asperen, Christi J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ACTIN BINDING PROTEIN; FGFR2 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; LSP1 PROTEIN, HUMAN; MAP3K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; TNRC9 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 8Q; CHROMOSOME 8Q24; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DUTCHMAN; FAMILY HISTORY; FEMALE; FGFR2 GENE; FIRST-DEGREE RELATIVE; GENE; GENE FREQUENCY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LOW RISK POPULATION; LSP1 GENE; MAJOR CLINICAL STUDY; MALE; MAP3K1 GENE; OVARY CANCER; PROSPECTIVE STUDY; SECOND-DEGREE RELATIVE; SINGLE NUCLEOTIDE POLYMORPHISM; TNRC9 GENE; TUMOR VOLUME; BREAST TUMOR; CHROMOSOME 8; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; LYMPH NODE METASTASIS; MIDDLE AGED; NETHERLANDS;

ADULT; AGED; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 8; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; LYMPHATIC METASTASIS; MAP KINASE KINASE KINASE 1; MICROFILAMENT PROTEINS; MIDDLE AGED; NETHERLANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, PROGESTERONE;

EID: 40349100347     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1793     Document Type: Article

References (27)

1. Collaborative Group on Hormonal Factors in Breast Cancer: Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58209 women with breast cancer and 101986 women without the disease. Lancet. 2001, 358: 1389-1399 10.1016/S0140-6736(01)06524-2.
2. Walsh T, King M-C: Ten genes for inherited breast cancer. Cancer Cell. 2007, 11: 103-105 10.1016/j.ccr.2007.01.010.
3. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR: Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999, 91: 943-949 10.1093/jnci/91.11.943.
4. Pharoah PD, Dunning AM, Ponder BA, Easton DF: Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004, 4: 850-860 10.1038/nrc1476.
5. Shaag A, Walsh T, Renbaum P, Kirchhoff T, Nafa K, Shiovitz S, Mandell JB, Welcsh P, Lee MK, Ellis N, et al: Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population. Hum Mol Genet. 2005, 14: 555-563 10.1093/hmg/ddi052.
6. Peto J, Mack TM: High constant incidence in twins and other relatives of women with breast cancer. Nat Genet. 2000, 26: 411-414 10.1038/82533.
7. Smith P, McGuffog L, Easton DF, Mann GJ, Pupo GM, Newman B, Chenevix-Trench G, kConFab Investigators, Szabo C, Southey M, et al: A genome wide linkage search for breast cancer susceptibility genes. Genes Chromosomes Cancer. 2006, 45: 646-655 10.1002/gcc.20354.
8. The CHEK2 Breast Cancer Case-Control Consortium: CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from ten studies. Am J Hum Genet. 2004, 74: 1175-1182 10.1086/421251.
9. Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, et al: Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006, 38: 1239-1241 10.1038/ng1902.
10. Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, Reid S, Spanova K, Barfoot R, Chagtai T, et al: PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007, 39: 165-167 10.1038/ng1959.
11. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, Struewing JP, Morrison J, Field H, Luben R, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007, 447: 1087-1095 10.1038/nature05887.
12. Lakhani SR, Jacquemier J, Sloane JP, Gusterson BA, Anderson TJ, Van de Vijver MJ, Farid LM, Venter D, Antoniou A, Storfer-Isser A, et al: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst. 1998, 90: 1138-1145 10.1093/jnci/90.15.1138.
13. Lakhani SR, Van de Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002, 20: 2310-2318 10.1200/JCO.2002.09.023.
14. de Bock GH, Schutte M, Krol-Warmerdam EMM, Seynaeve C, Blom J, Brekelmans CTM, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, et al: Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant. J Med Genet. 2004, 41: 731-735 10.1136/jmg.2004.019737.
15. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van 'tVeer LJ: Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. J Clin Oncol. 2007, 25: 64-69 10.1200/JCO.2006.06.3024.
16. Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer EJ, Van Asperen CJ, Hoogerbrugge N, van Leeuwen I, Vasen HF, Cleton-Jansen AM, Kraan J, Houwing-Duistermaat JJ, et al: Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping. Clin Cancer Res. 2006, 12: 1693-1700 10.1158/1078-0432.CCR-05-2230.
17. Netherlands Cancer Registry, Incidentie van kanker naar 5-jaarsleeftijdsgroepen, lokalisatie en geslacht, 1997-2003. [ http://www.iKCnet.nl/page.php?id=1865&nav_id=41 ]
18. Honrado E, Benitez J, Palacios J: Histopathology of BRCA1- and BRCA2-associated breast cancer. Crit Rev Oncol Hematol. 2006, 59: 27-39 10.1016/j.critrevonc.2006.01.006.
19. van der Groep P, Bouter A, van der Zanden R, Siccama I, Menko FH, Gille JJ, van Kalken C, van der Wall E, Verheijen RH, van Diest PJ: Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol. 2006, 59: 611-617 10.1136/jcp.2005.032151.
20. Hartman M, Czene K, Reilly M, Bergh J, Lagiou P, Trichopoulos D, Adami HO, Hall P: Genetic implications of bilateral breast cancer: a population-based cohort study. Lancet Oncol. 2005, 6: 377-382 10.1016/S1470-2045(05)70174-1.
21. Jacobi CE, Jonker MA, Nagelkerke NJ, van Houwelingen JC, de Bock GH: Prevalence of family histories of breast cancer in the general population and the incidence of related seeking of health care. J Med Genet. 2003, 40: e83. 10.1136/jmg.40.7.e83.
22. Hunter DJ, Kraft P, Jacobs KB, Cox DG, Yeager M, Hankinson SE, Wacholder S, Wang Z, Welch R, Hutchinson A, et al: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 2007, 39: 870-874 10.1038/ng2075.
23. Steele IA, Edmondson RJ, Leung HY, Davies BR: Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors. 2006, 24: 45-53 10.1080/08977190500361697.
24. Steele IA, Edmondson RJ, Bulmer JN, Bolger BS, Leung HY, Davies BR: Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene. 2001, 20: 5878-5887 10.1038/sj.onc.1204755.
25. Titus-Ernstoff L, Egan KM, Newcomb PA, Baron JA, Stampfer M, Greenberg ER, Cole BF, Ding J, Willett W, Trichopoulos D: Exposure to breast milk in infancy and adult breast cancer risk. J Natl Cancer Inst. 1998, 90: 921-924 10.1093/jnci/90.12.921.
26. de Bock GH, Mourits MJ, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, et al: Association between the CHEK2*1100delC germ line mutation and estrogen receptor status. Int J Gynecol Cancer. 2006, 16: 552-555 10.1111/j.1525-1438.2006.00694.x.
27. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, Gudjonsson SA, Masson G, Jakobsdottir M, Thorlacius S, Helgason A, et al: Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2007, 39: 865-869 10.1038/ng2064.